Umoja Biopharma
Seattle
About Umoja Biopharma
Umoja Biopharma focuses on innovative immunotherapy by reprogramming T cells within the patient's body to target cancer effectively. The company offers scalable therapeutic regimens designed for solid tumors and hematological cancers that typically respond poorly to current treatments. Its in-house CAR T-cell gene therapy platform aims to improve patient outcomes across various stages of cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $363.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2025)
- Website: umoja-biopharma.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/umoja-biopharma-45659 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.